Compare Globus Medical Inc. Class A Common Stock (GMED) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs TORM plc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while TORM plc trades at $39.12 (market cap $4.12B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.5× TORM plc's market cap, and TORM plc pays a 11.07% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and TORM plc for 23 Days on average.
| GMED | TRMD | |
|---|---|---|
Market Cap | $10.25B | $4.12B |
Volume | 1,059,528 | 2,428,655 |
Sector | Health | Industrials |
52-Week High | $96.82 | $41.11 |
52-Week Low | $58.33 | $19.39 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $9.76B | $4.83B |
Dividend Yield | — | 11.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
TRMD trades at $41.11, up 0.46% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.76, net income margin of 35.52%, and ROE of 26.84%. Recent earnings show mixed results with Q2 2026 missing expectations but strong year-over-year growth projected. Analyst consensus is unanimously bullish with 100% buy ratings. The stock faces headwinds from declining spot rates as noted in recent analysis.
Outlook remains positive based on strong profitability and valuation metrics, though near-term pressure from freight rate declines presents risk. The dividend yield of approximately 5.8% provides income support. Institutional accumulation and solid cash flow generation support the bullish case, but investors should monitor tanker rate trends closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
